Listing 3 - Actual negotiations

Indication:

Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients

Indication:

Advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma in adult patients (in combination with fluoropyrimidine- and platinum-containing chemotherapy)

Indication:

Esophageal or gastroesophageal junction cancer, completely resected, adjuvant treatment in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT)

Indication:

Heart failure, NYHA class II or III

Indication:

Heart failure, NYHA class II or III

Indication:

Wilson's Disease

Indication:

Psoriatic Arthritis

Indication:

Rheumatoid Arthritis

Indication:

Epilepsy

Indication:

Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) in adults with previously treated CCA with a FGFR2 fusion or other rearrangement